ADC Therapeutics (ADCT) news
Recent news
ADC Therapeutics SA - Q2 net product revenue of $18.6 million, net loss $0.11 per share
AInvest Wire · Aug 13, 2026Whitehawk Therapeutics - BioCytoGen to receive upfront payment, milestone payments, and low single-digit royalties
Biocytogen Pharmaceuticals (HKEX: 02315) has entered into a licensing agreement with Tubulis, an ADC therapeutics developer, granting the latter global rights to a fully human antibody generated using Biocytogen’s proprietary RenMice® platform. Under the terms of the agreement, Biocytogen will…
AInvest Wire · Jul 7, 2026ADC Therapeutics - full Lotis-7 data expected in Q4 2026
ADC Therapeutics (NYSE: ADCT) announced the completion of enrollment in its LOTIS-7 Phase 1b clinical trial, which evaluates ZYNLONTA® in combination with glofitamab for patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The trial, which enrolled 100 patients at the…
AInvest Wire · Jun 30, 2026ADC Therapeutics - planned workforce reduction expected to generate annualized savings of about $10 mln
AInvest Wire · Jun 24, 2026ADC Therapeutics - preparing for pre-SBLA meeting with FDA in August 2026
AInvest Wire · Jun 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.